Scientific approaches to defining HPV vaccine-induced protective immunity

被引：0
作者：
Lehtinen, Matti [1 ,2 ]
van Damme, Pierre [3 ]
Beddows, Simon [4 ]
Pinto, Ligia A. [5 ]
Mariz, Filipe [6 ]
Gray, Penelope [2 ]
Dillner, Joakim [2 ]
机构：
[1] Inst Hlth & Welf, Dept Vaccines, Helsinki, Finland
[2] Karolinska Inst, Ctr Cerv Canc Eliminat, Dept Clin Sci Intervent & Technol, Stockholm, Sweden
[3] Univ Antwerp, Ctr Evaluat Vaccinat Vaccinopolis, Antwerp, Belgium
[4] UK Hlth Secur Agcy, Virus Reference Dept, Publ Hlth Microbiol Div, London, England
[5] Frederick Natl Lab Canc Res, HPV Serol Lab, Frederick, MD USA
[6] Deutsch Krebsforschungszentrum, Div Infect & Canc, Heidelberg, Germany
来源：
INTERNATIONAL JOURNAL OF CANCER | 2025年
基金：
美国国家卫生研究院;
关键词：
antibody; cancer; hepatitis B virus; human papillomavirus; vaccine; HUMAN-PAPILLOMAVIRUS HPV; COMBINED HEPATITIS-A; QUADRIVALENT HPV; B-VIRUS; ANTIBODIES; INFECTION; ANTIGEN; STANDARDIZATION; MECHANISMS; PREVENTION;
D O I：
10.1002/ijc.35345
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Seventeen years after the licensure of prophylactic human papillomavirus (HPV) L1 virus-like-particle vaccines, a defined antibody level that correlates with vaccine-induced protection against HPV infections and associated neoplasia is missing. In contrast, correlates of protection have been defined for many viral vaccines, including for the hepatitis B virus (HBV) vaccine. This review includes lessons learned from vaccination against HBV and the use of an established protective HBV surface antigen antibody level: 10 mIU/mL, an overview of HPV infection-induced and HPV vaccine-induced antibody responses, successful efforts to establish international standardization of serological reagents and associated tools, and 15-year vigilance of HPV vaccine-induced antibody levels in a vaccination cohort against breakthrough infections. This report identifies progress but also gaps on the journey toward the definition of a HPV vaccine-induced correlate of protection.
引用
收藏
页码：1848 / 1857
页数：10
相关论文
共 92 条
  • [1] Public assessment report, (2006)
  • [2] Public assessment report, (2007)
  • [3] Jack A.D., Hall A.J., Maine N., Mendy M., Whittle H.C., What level of hepatitis B antibody is protective?, J Infect Dis, 179, pp. 489-492, (1999)
  • [4] Olakunde B.O., Ifeorah I.M., Adeyinka D.A., Et al., Immune response to hepatitis B vaccine among children under 5 years in Africa: a meta-analysis, Trop Med Health, 58, (2024)
  • [5] Van Damme P., Leroux-Roels G., Suryakiran P., Et al., Persistence of antibodies 20 years after vaccination with a combined hepatitis a and B vaccine, Hum Vaccin Immunother, 13, pp. 972-980, (2017)
  • [6] Gilca V., Sauvageau C., Boulianne N., Et al., Immunogenicity of quadrivalent HPV and combined hepatitis a/B vaccine when co-administered or administered one month apart to 9-10 year-old girls according to 0-6 mo schedule, Hum Vaccin Immunother, 10, pp. 2438-2445, (2014)
  • [7] Zheng Z., Li G., Liao F., Et al., Seroconversion of hepatitis B surface antigen among those with previously successful immune response in southern China, Hum Vac Immunother, 17, pp. 845-851, (2021)
  • [8] Leuridan E., Van Damme P., Hepatitis B and the need for a booster dose, Clin Infect Dis, 53, pp. 68-75, (2011)
  • [9] Schiller J., Lowy D., Explanations for the high potency of HPV prophylactic vaccines, Vaccine, 36, pp. 4768-4773, (2018)
  • [10] Amanna I.J., Slifka M.K., Mechanisms that determine plasma cell lifespan and the duration of humoral immunity, Immunol Rev, 236, pp. 125-138, (2010)
12345678910